These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32800519)

  • 1. Effect of Prophylactic Post-transplant Ponatinib Administration on Outcomes in Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
    Nanno S; Matsumoto K; Nakamae M; Okamura H; Nishimoto M; Hirose A; Koh H; Nakashima Y; Nakane T; Morita K; Hino M; Nakamae H
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):813-819.e1. PubMed ID: 32800519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
    Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
    Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.
    Chen H; Xu LP; Zhang XH; Wang Y; Chen YH; Yan CH; Cheng YF; Han W; Chen Y; Qin YZ; Liu Y; Chang YJ; Liu KY; Huang XJ
    Leuk Res; 2022 Oct; 121():106930. PubMed ID: 36007342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
    Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
    J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.
    Leotta S; Markovic U; Pirosa MC; Stella S; Tringali S; Martino M; Specchia G; Carluccio P; Risitano AM; Grimaldi F; Vigna E; Palmieri F; Palmieri R; Annunziata M; Pisapia G; Palazzo G; Milone GA; Pelle AC; Scalise L; Di Giorgio MA; Bulla A; Leotta V; Di Raimondo F; Milone G
    Ann Hematol; 2021 Jul; 100(7):1743-1753. PubMed ID: 33774681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
    Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
    Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
    Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
    Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Sanford DS; Kantarjian H; O'Brien S; Jabbour E; Cortes J; Ravandi F
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):365-73. PubMed ID: 25764322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
    He JB; Zhang X; Guo ZW; Liu MM; Xu N; Huang F; Fan ZP; Xuan L; Deng L; Lin SH; Xu J; Sun J; Liu QF
    Int J Cancer; 2020 Aug; 147(4):1071-1077. PubMed ID: 31785158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ribera JM; García-Calduch O; Ribera J; Montesinos P; Cano-Ferri I; Martínez P; Esteve J; Esteban D; García-Fortes M; Alonso N; González-Campos J; Bermúdez A; Torrent A; Genescà E; Mercadal S; Martínez-Lopez J; García-Sanz R
    Blood Adv; 2022 Sep; 6(18):5395-5402. PubMed ID: 35675590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan.
    Takahashi N; Kondo T; Ikari Y; Fukumoto Y; Hatake K; Masunari A; Nishibayashi S; Kageyama A; Fukuta Y; Tojo A
    Jpn J Clin Oncol; 2024 Aug; 54(8):930-938. PubMed ID: 38747937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.
    Renzi D; Marchesi F; De Angelis G; Elia L; Salvatorelli E; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Arcese W; Mengarelli A;
    Chemotherapy; 2017; 62(1):58-61. PubMed ID: 27618144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with ponatinib in paediatric patients with leukaemia.
    Rossoff J; Huynh V; Rau RE; Macy ME; Sulis ML; Schultz KR; Burke MJ; Athale U; O'Brien MM; Gregory JJ; van der Sluis IM; Keller FG; Zwaan CM; Suttorp M; Hijiya N
    Br J Haematol; 2020 Apr; 189(2):363-368. PubMed ID: 31975387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Othman T; Koller P; Tsai NC; Yang D; Pourhassan H; Agrawal V; Ngo D; Chen J; Farol L; Spielberger R; Sahebi F; Al Malki MM; Cai JL; Sandhu KS; Mansour J; Salhotra A; Ali H; Aribi A; Arslan S; Marcucci G; Forman SJ; Stein AS; Nakamura R; Pullarkat V; Aldoss I; Mei M
    Am J Hematol; 2024 Sep; 99(9):1680-1690. PubMed ID: 38804599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents?
    Sohn SK; Lee JM; Jang Y; Lee Y; Na J; Cho HJ; Moon JH; Baek DW
    Expert Rev Hematol; 2024 Jul; 17(7):353-359. PubMed ID: 38755522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to ponatinib before hematopoietic stem cell transplantation in a child with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yamamoto M; Hori T; Igarashi K; Shimada H; Tsutsumi H
    Pediatr Int; 2018 Jan; 60(1):85-87. PubMed ID: 29356285
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
    Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
    Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
    DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.